StockNews.AI

Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results

StockNews.AI • 1 minute

CAICMPTASHABEO
High Materiality9/10

Information

Full year revenue growth of approximately 94% driven by strong performance  in molecular profiling s...

Original source

AI Summary

Caris Life Sciences announced strong preliminary financial results for 2025 with a 94% revenue growth, mainly driven by molecular profiling services. This growth underscores their expanding market position in precision medicine and is expected to positively influence investor sentiment ahead of their presentation at the J.P. Morgan Healthcare Conference.

Sentiment Rationale

Caris's robust revenue growth reflects strong demand for its services, comparable to past successful quarters of similar biotech firms that saw share appreciation following strong earnings reports.

Trading Thesis

Buy CAI ahead of the J.P. Morgan Conference to capitalize on bullish momentum.

Market-Moving

  • Strong 2025 revenue growth suggests increased investor confidence in CAI's business model.
  • Presentation at the J.P. Morgan Conference may trigger further positive analyst coverage.
  • Liquidity position indicates stability, reducing concerns about financial distress.
  • Preliminary results set high expectations, could lead to upward revisions in price targets.

Key Facts

  • Caris reported fourth quarter 2025 revenue of approximately $281 million, up 116%.
  • Full year revenue grew by about 94% to approximately $800 million.
  • The CEO highlighted significant growth in molecular profiling through increased clinical adoption.
  • Company plans to present detailed results at the J.P. Morgan Healthcare Conference.
  • Preliminary cash and equivalents reached approximately $802 million, stable liquidity position.

Companies Mentioned

  • Caris Life Sciences (CAI): Strong performance in molecular profiling boosts revenue forecasts.

Earnings

This falls under 'Earnings' as it highlights Caris’s significant revenue growth and financial performance, making it relevant for investors focused on company fundamentals and potential market performance.

Caris Life Sciences Reports Remarkable Preliminary Fourth Quarter and Full Year 2025 Results

NASDAQ: CAI - Caris Life Sciences, a pioneering force in precision medicine and next-generation AI TechBio, has announced its preliminary unaudited financial results for Q4 and the entirety of fiscal year 2025. The company reported a significant growth trajectory, showcasing the efficacy of its molecular profiling services.

Fourth Quarter 2025 Financial Overview

For the three-month period ending December 31, 2025, Caris Life Sciences achieved total revenues of approximately $281 million, marking an impressive increase of around 116% compared to the same timeframe in 2024. This revenue surge is primarily attributed to:

  • Approximately $270 million generated from molecular profiling services (which includes about $81 million in prior period true-ups).
  • About $11 million from pharmaceutical research and development services.

During this quarter, the company completed about 52,700 clinical therapy selection cases, which reflects an increase of approximately 20%. The breakdown of these cases includes approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.

Full Year 2025 Financial Highlights

For the fiscal year ending December 31, 2025, Caris reported total revenues of almost $800 million, representing a remarkable growth of 94% year-on-year. Key components of this revenue included:

  • Approximately $755 million from molecular profiling services (inclusive of around $33 million in prior year true-ups).
  • Approximately $45 million attributable to pharma research and development services.

During the full year, Caris completed around 199,300 clinical therapy selection cases, translating to a 22% increase from the previous year. This consists of approximately 170,300 MI Profile cases and about 29,000 Caris Assure cases.

Strong Cash Position

As of December 31, 2025, Caris Life Sciences reported preliminary unaudited cash, cash equivalents, restricted cash, and marketable securities totaling approximately $802 million, showcasing a net increase of around $43 million from September 30, 2025.

Leadership Commentary

David D. Halbert, Founder, Chairman, and CEO, expressed enthusiasm about the company's achievements: "2025 was a breakthrough year for Caris as we became a public company and demonstrated the scale and impact of our comprehensive molecular profiling platform. We continue to focus on expanding clinical adoption, advancing a differentiated pipeline, and building the foundation for what we believe will be a new standard in precision medicine."

Upcoming Presentation

This announcement precedes Caris Life Sciences' presentation today at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 PM Pacific Time. The presentation will cover these financial results along with additional business updates. For those interested, materials and webcasts will be available on the company's investor relations website.

Future Guidance and Reporting

Caris Life Sciences has noted that the financial information provided is preliminary and unaudited. The final results may differ as the company completes its customary year-end reviews and preparations. Complete Q4 and full year 2025 financial results are expected to be announced during the earnings call scheduled for late February 2026.

About Caris Life Sciences

Caris Life Sciences® is at the forefront of precision medicine, developing cutting-edge solutions through comprehensive molecular profiling such as Whole Exome and Whole Transcriptome Sequencing. The company leverages advanced AI and machine learning technologies to create a unique platform designed to improve patient outcomes in healthcare.

Headquartered in Irving, Texas, Caris operates internationally with offices in several major cities including Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland.

Related News